| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P2093 | author name string | Wei Pan | |
| Hongcheng Zhu | |||
| Xinchen Sun | |||
| Yan Yang | |||
| Rongping Zhou | |||
| Youcheng Zhang | |||
| P2860 | cites work | KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib | Q21563446 |
| Global cancer statistics | Q22241238 | ||
| Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers | Q24611043 | ||
| Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials | Q24625201 | ||
| The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis | Q24650902 | ||
| Cancer treatment and survivorship statistics, 2012 | Q27020961 | ||
| Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy | Q27313799 | ||
| Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones | Q27851527 | ||
| Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas | Q27851860 | ||
| The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. | Q27852021 | ||
| Practical methods for incorporating summary time-to-event data into meta-analysis | Q28131754 | ||
| KRAS mutations in non-small cell lung cancer | Q28240568 | ||
| Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR | Q29547545 | ||
| Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer | Q29618155 | ||
| The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study | Q30539397 | ||
| Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts | Q33682941 | ||
| The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer. | Q34317490 | ||
| Selective targeting of KRAS-mutant cells by miR-126 through repression of multiple genes essential for the survival of KRAS-mutant cells | Q34365804 | ||
| Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2). | Q34415439 | ||
| Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. | Q34533636 | ||
| Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials | Q34619163 | ||
| Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer | Q34749852 | ||
| Common and rare EGFR and KRAS mutations in a Dutch non-small-cell lung cancer population and their clinical outcome. | Q34906960 | ||
| American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy | Q34935716 | ||
| Impact of KRAS mutation on response and outcome of patients with stage III non-squamous non-small cell lung cancer | Q36262860 | ||
| The ras oncogenes in human lung cancer | Q38004386 | ||
| KRAS mutations in lung cancer | Q38057476 | ||
| Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations | Q38405477 | ||
| Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer | Q38412416 | ||
| KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer | Q38432430 | ||
| KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies | Q39213209 | ||
| Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer | Q39466460 | ||
| Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung | Q40168927 | ||
| Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial. | Q41548711 | ||
| Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma | Q42771554 | ||
| KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma. | Q43167252 | ||
| KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value | Q43526022 | ||
| Prognostic implications of epidermal growth factor receptor and KRAS gene mutations and epidermal growth factor receptor gene copy numbers in patients with surgically resectable non-small cell lung cancer in Taiwan | Q43756247 | ||
| The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients. | Q44197652 | ||
| A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation | Q44242530 | ||
| Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer | Q44425380 | ||
| KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy | Q44658636 | ||
| Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer | Q44846520 | ||
| Origin and prognostic value of circulating KRAS mutations in lung cancer patients | Q45017062 | ||
| Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)? | Q45732573 | ||
| Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status. | Q45930127 | ||
| Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacy. | Q45989147 | ||
| Impact of epidermal growth factor receptor and KRAS mutations on clinical outcome in resected non-small cell lung cancer patients. | Q46046144 | ||
| Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. | Q46484712 | ||
| Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib | Q46618741 | ||
| Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status | Q48924508 | ||
| Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy. | Q53055406 | ||
| The efficacy of first-line chemotherapy is associated with KRAS mutation status in patients with advanced non-small cell lung cancer: a meta-analysis. | Q53165144 | ||
| Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)? | Q53243471 | ||
| Should KRAS mutation still be used as a routine predictor of response to EGFR-TKIs in advanced non-small-cell lung cancer? A revaluation based on meta-analysis. | Q53647606 | ||
| The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma. | Q54194782 | ||
| KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making. | Q54440829 | ||
| [Relationship between EGFR and KRAS mutations and prognosis in Chinese patients with non-small cell lung cancer: a mutation analysis with real-time polymerase chain reaction using scorpion amplification refractory mutation system]. | Q54458363 | ||
| Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. | Q54577559 | ||
| Prognostic value ofTP53,KRASandEGFRmutations in nonsmall cell lung cancer: the EUELC cohort | Q57419582 | ||
| Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a Large Cohort of Japanese Patients with Surgically Treated Lung Adenocarcinoma | Q58454678 | ||
| Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma | Q59566032 | ||
| Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype | Q61899364 | ||
| K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung | Q68532141 | ||
| BRAF and RAS mutations in human lung cancer and melanoma | Q78598197 | ||
| Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas | Q83223432 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | meta-analysis | Q815382 |
| P304 | page(s) | 8373-8388 | |
| P577 | publication date | 2016-01-30 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies | |
| P478 | volume | 7 |
| Q49667322 | An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer |
| Q87750075 | Analysis of the clinicopathologic characteristics and prognostic of stage I invasive mucinous adenocarcinoma |
| Q47234596 | Blocking transferrin receptor inhibits the growth of lung adenocarcinoma cells in vitro. |
| Q37536958 | Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer |
| Q64234032 | Clinicopathological features and clinical efficacy of crizotinib in Chinese patients with -positive non-small cell lung cancer |
| Q58575063 | Comprehensive Validation of Snapback Primer-Based Melting Curve Analysis to Detect Nucleotide Variation in the Codon 12 and 13 of KRAS Gene |
| Q48255019 | Concurrent ROS1 gene rearrangement and KRAS mutation in lung adenocarcinoma: A case report and literature review |
| Q37619866 | DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine. |
| Q41603225 | Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine. |
| Q33591865 | KRAS and TP53 mutations in inflammatory bowel disease-associated colorectal cancer: a meta-analysis |
| Q64884734 | KRAS mutation and DNA repair and synthesis genes in non-small-cell lung cancer. |
| Q28077570 | KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patients |
| Q49887897 | KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target |
| Q33778007 | Liquoral liquid biopsy in neoplastic meningitis enables molecular diagnosis and mutation tracking: a proof of concept. |
| Q38902588 | Mutational Profile from Targeted NGS Predicts Survival in LDCT Screening-Detected Lung Cancers. |
| Q55070937 | NF-κB inhibition by dimethylaminoparthenolide radiosensitizes non-small-cell lung carcinoma by blocking DNA double-strand break repair. |
| Q38663069 | Selumetinib for the treatment of non-small cell lung cancer |
| Q39660590 | Specific KRAS amino acid substitutions and EGFR mutations predict site-specific recurrence and metastasis following non-small-cell lung cancer surgery. |
| Q92826289 | Targeted Gene Next-Generation Sequencing Panel in Patients with Advanced Lung Adenocarcinoma: Paving the Way for Clinical Implementation |
| Q64062553 | The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer |
| Q91253691 | The genetic landscape of 87 ovarian germ cell tumors |
| Q42820759 | Treating KRAS-mutant NSCLC: latest evidence and clinical consequences |
Search more.